298 related articles for article (PubMed ID: 22462686)
1. Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy.
Ahmad M; Hamid A; Hussain A; Majeed R; Qurishi Y; Bhat JA; Najar RA; Qazi AK; Zargar MA; Singh SK; Saxena AK
DNA Cell Biol; 2012 Oct; 31 Suppl 1():S62-71. PubMed ID: 22462686
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
4. Targeting histone deacetylase in thyroid cancer.
Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
[TBL] [Abstract][Full Text] [Related]
5. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
6. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Jazirehi AR
Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
8. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
Botrugno OA; Santoro F; Minucci S
Cancer Lett; 2009 Aug; 280(2):134-44. PubMed ID: 19345000
[TBL] [Abstract][Full Text] [Related]
10. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
11. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic alterations and cancer: new targets for therapy.
Allen A
IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
[TBL] [Abstract][Full Text] [Related]
13. H3K9 acetylation and radial chromatin positioning.
Strasák L; Bártová E; Harnicarová A; Galiová G; Krejcí J; Kozubek S
J Cell Physiol; 2009 Jul; 220(1):91-101. PubMed ID: 19248079
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of tumor cells by targeting histone deacetylases.
Perego P; Zuco V; Gatti L; Zunino F
Biochem Pharmacol; 2012 Apr; 83(8):987-94. PubMed ID: 22120677
[TBL] [Abstract][Full Text] [Related]
15. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
Weidle UH; Grossmann A
Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of histone deacetylases.
Huang Y; Shaw PG; Davidson NE
Methods Mol Biol; 2011; 791():297-311. PubMed ID: 21913088
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ; Johnstone RW; Bolden JE
Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy.
Lin KT; Wang YW; Chen CT; Ho CM; Su WH; Jou YS
Clin Cancer Res; 2012 Sep; 18(17):4691-701. PubMed ID: 22811583
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation of airway inflammation.
Adcock IM; Tsaprouni L; Bhavsar P; Ito K
Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]